Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Long-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Profusa (NVACW) Shares Repurchased (2023 - 2025)

Profusa posted quarterly Shares Repurchased of $6.5 million for Q1 2025, up 145.37% year-on-year from $2.7 million in Q1 2024, and up 993.45% on a QoQ basis from $595439.0 in Q4 2024.

Profusa (NVACW) has 3 years of Shares Repurchased data on file, last reported at $6.5 million in Q1 2025.

  • For the quarter ending Q1 2025, Shares Repurchased rose 145.37% year-over-year to $6.5 million; the trailing twelve-month figure through Jun 2025 stood at $7.1 million (up 167.81% YoY), and the FY2024 full-year result was $3.2 million, down 98.24% from the prior year.
  • Shares Repurchased for Q1 2025 stood at $6.5 million, up from $595439.0 in the prior quarter.
  • Across five years, Shares Repurchased topped out at $184.8 million in Q1 2023 and bottomed at $595439.0 in Q4 2024.
  • The 3-year median for Shares Repurchased is $4.6 million (2024), against an average of $48.7 million.
  • The widest annual swing landed in 2024, when Shares Repurchased slumped 98.56%; it then jumped 145.37% in 2025.
  • A 3-year view of Shares Repurchased shows it stood at $184.8 million in 2023, then slumped by 99.68% to $595439.0 in 2024, then surged by 993.45% to $6.5 million in 2025.
  • The last three Shares Repurchased figures came in at $6.5 million (Q1 2025), $595439.0 (Q4 2024), and $2.7 million (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 Profusa - - - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 6.51 Mn
Mar 31, 2025 6.51 Mn
Dec 31, 2024 595,439.00
Dec 31, 2024 595,439.00
Mar 31, 2024 2.65 Mn
Mar 31, 2024 2.65 Mn
Mar 31, 2023 184.85 Mn
Mar 31, 2023 184.85 Mn